IOVA - Iovance Biotherapeutics, Inc.
24.72 0.00 (0.00%)
After hours: 4:54PM EST
| Previous Close | 24.87 |
| Open | 24.96 |
| Bid | 24.71 x 2900 |
| Ask | 24.72 x 1400 |
| Day's Range | 24.41 - 25.00 |
| 52 Week Range | 7.26 - 26.59 |
| Volume | 977,657 |
| Avg. Volume | 1,322,760 |
| Market Cap | 3.12B |
| Beta (3Y Monthly) | 2.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.36 |
| Earnings Date | Feb 25, 2020 - Mar 2, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.25 |
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Iovance Biotherapeutics, Inc. (IOVA)
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
- Simply Wall St.
We Think Iovance Biotherapeutics (NASDAQ:IOVA) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. By way of example, Iovance...
- GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in December
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. The company is currently conducting pivotal studies in patients with metastatic melanoma and advanced cervical cancer. In addition, the company’s TIL therapies are being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including head and neck and non-small cell lung cancer.
- GlobeNewswire
Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy
Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced results of a subgroup analysis of Cohort 2 of the Phase 2 lifileucel metastatic melanoma study C-144-01 in patients who were primary refractory to prior anti-PD-1/L1 therapy. In the subgroup analysis conducted for primary refractory patients in our Cohort 2 of the C-144-01 study, TIL demonstrates excellent efficacy and durability of response thus far.
- ETF Trends
The Unloved Biotechnology ETF Rally
Biotechnology stocks have been outperforming over the past month, but ETF investors seem disinterested and are even trimming exposure to this sector. In a weekly update on the flow of money in and out of stock funds, PiperJaffray analyst Christopher J. Raymond pointed out that investors pulled a net $99 million out of healthcare and biotech-related funds in the one-week period ended on Wednesday, Barron's reports. The latest redemptions seems surprising given the recent outperformance of the biotechnology sector.
- GlobeNewswire
Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer 34th Annual Meeting
Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that new data from Cohort 2 of the ongoing Phase 2 lifileucel metastatic melanoma study (C-144-01) were presented Friday, Nov. 8, 2019, at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting in National Harbor, Maryland (Abstract P865). Median DOR was not reached as assessed by either IRC (range: 1.6+ to 21.2+ months) or investigator (range: 2.2 to 21.2+ months) at 11.3 months median follow up. In addition, based on the most recent data cut from the study, median DOR was not reached as assessed by investigator at 12.8 months of median study follow-up.
- GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November
Iovance Biotherapeutics intends to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer.
- GlobeNewswire
Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results
- Late-breaking abstract at Society for Immunotherapy of Cancer (SITC) meeting to feature Independent Review Committee (IRC) read results from Cohort 2 of C-144-01.
- GlobeNewswire
Iovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Monday, November 4, 2019
Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its third quarter 2019 financial results on Monday, November 4, 2019. The live webcast can be accessed under “News & Events” in the Investors section of the Company’s website at www.iovance.com or at the link: https://edge.media-server.com/mmc/p/9ohu47kv. Iovance Biotherapeutics intends to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers.
- Insider Monkey
Hedge Funds Are Dumping Iovance Biotherapeutics, Inc. (IOVA)
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
- GlobeNewswire
Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting
Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that four abstracts highlighting its TIL therapy will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting from November 6-10, 2019 in National Harbor, Maryland. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer.
- Benzinga
Stifel Bullish On Iovance And Fate Therapeutics, Neutral On Bluebird Bio
Stifel initiated coverage on a trio of oncology-focused biotechs Tuesday, recommending buying two and staying sidelined on a third. The Analyst Benjamin Burnett initiated coverage of: bluebird bio Inc ...
- GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Conferences
Live and archived webcasts of the Cell & Gene Meeting on the Mesa and 2019 Cantor Global Healthcare Conference presentations will be available in the Investors section of the Iovance website at http://ir.iovance.com. Iovance Biotherapeutics intends to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer.
- Simply Wall St.
Have Insiders Been Buying Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares This Year?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
- TheStreet.com
Iovance Biotherapeutics: Technical Analysis and Strategy
Iovance Biotherapeutics is worth speculating on, as the company's cancer treatments are promising, Jim Cramer said during his Mad Money program Friday night. IOVA intends to commercialize "autologous cell therapy products for solid tumors and blood cancers." Their approach uses a patient's own immune cells to attack cancer cells -- cutting edge stuff, if you ask me. In the daily bar chart of IOVA, below, we can see that prices made a seven-plus month base around $10 before a gap to the upside got the rally going.
- Motley Fool
Iovance Biotherapeutics: Buy the Dip?
The company is flush with cash and wields a promising therapeutic pipeline. Is its recent tumble a buying opportunity?
- GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in September
Live and archived webcasts of the presentations will be available by visiting the Investors section of the Iovance Biotherapeutics website at http://ir.iovance.com. Iovance Biotherapeutics intends to commercialize autologous cell therapy products for solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer cells.
- Schaeffer's Investment Research
IOVA Stock Could See Another Massive Rebound
A bullish signal just flashed for IOVA that could have it trading back near its five-year highs
Motley FoolIovance Biotherapeutics, Inc. (IOVA) Q2 2019 Earnings Call Transcript
IOVA earnings call for the period ending June 30, 2019.
- Investor's Business Daily
Biotech Merger Activity Has Been Hot In 2019 — So, What's One More?
Iovance Biotherapeutics hit a "clear inflection point" in the second quarter, analysts said Friday — but that didn't stop the biotech stock from plunging on wider-than-expected losses.
- GlobeNewswire
Iovance Biotherapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
- Regulatory submission for LN-145 in advanced cervical cancer expected in the second half of 2020 -- Company to host conference call at 4:30 p.m. EDT today - SAN CARLOS,.
- Motley Fool
3 Top Biotech Stocks to Buy Right Now
These three biotech stocks might be outstanding buys right now.
- GlobeNewswire
Iovance Biotherapeutics to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1, 2019
Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its second quarter 2019 financial results on Thursday, August 1, 2019. Iovance Biotherapeutics intends to commercialize autologous cell therapy products for solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own cancer-fighting immune cells to attack solid tumors. TIL are extracted from tumor cells, and once expanded through a proprietary process are infused back into the patient.
- GlobeNewswire
Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein, M.D., as Chief Medical Officer
Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the appointment of Friedrich Graf Finckenstein, M.D., as chief medical officer. Dr. Graf Finckenstein brings over 19 years of experience in clinical development and translational research to the company. “We are very pleased to have Dr. Finckenstein join Iovance as we move forward with pivotal studies for lifileucel in metastatic melanoma and LN-145 in metastatic cervical cancer,” said Maria Fardis, Ph.D., president and chief executive officer of Iovance Biotherapeutics.
- Simply Wall St.
Does Market Volatility Impact Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Share Price?
If you own shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) then it's worth thinking about how it contributes to...
